LGND
Ligand Pharmaceuticals Incorporated
NASDAQ · USHealthcareBiotechnology
$293.99-3.10%
Price as of Jul 20, 2026
LGND financials
Ligand Pharmaceuticals Incorporated financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M |
| Cost of revenue | $6.6M | $11.1M | $35.0M | $52.8M |
| Gross profit | $261.5M | $156.1M | $96.3M | $143.4M |
| Operating expenses | $214.3M | $178.7M | $84.3M | $140.4M |
| Operating income | $47.2M | -$22.6M | $11.9M | $3.0M |
| Net income | $124.5M | -$4.0M | $52.2M | -$33.4M |
| EBITDA | $192.7M | $40.8M | $100.8M | $81.2M |
| Basic EPS | $6.44 | $-0.22 | $3.02 | $-1.98 |
| Diluted EPS | $6.13 | $-0.22 | $2.94 | $-1.98 |
| Balance sheet | ||||
| Cash & equivalents | $174.9M | $72.3M | $23.0M | $45.0M |
| Total assets | $1.6B | $941.8M | $787.2M | $762.7M |
| Total liabilities | $543.4M | $111.3M | $86.3M | $165.2M |
| Stockholders’ equity | $1.0B | $830.4M | $700.9M | $597.5M |
| Total debt | $451.5M | $7.1M | $6.2M | $87.7M |
| Net debt | $276.6M | -$65.2M | -$16.8M | $42.7M |
| Cash flow | ||||
| Operating cash flow | $49.4M | $97.0M | $49.6M | $137.8M |
| Capital expenditure | -$452.0K | -$19.6M | -$53.8M | -$17.9M |
| Free cash flow | $48.9M | $77.4M | -$4.3M | $119.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$15.0M | $0.00 | $0.00 | $0.00 |